Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.

Udd KA, Bujarski S, Wirtschafter E, Spektor TM, Ghermezi M, Rassenti LZ, David ME, Nosrati JD, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Kipps TJ, Berenson JR.

Target Oncol. 2019 Oct;14(5):551-561. doi: 10.1007/s11523-019-00666-0.

PMID:
31473933
2.

The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker.

Sanchez E, Tanenbaum EJ, Patil S, Li M, Soof CM, Vidisheva A, Waterman GN, Hekmati T, Tang G, Wang CS, Chen H, Berenson J.

Expert Rev Mol Diagn. 2018 Apr;18(4):319-329. doi: 10.1080/14737159.2018.1448269. Epub 2018 Mar 7. Review.

PMID:
29504446
3.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
4.
5.

Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.

Maglione PJ, Ko HM, Tokuyama M, Gyimesi G, Soof C, Li M, Sanchez E, Chen H, Radigan L, Berenson J, Cunningham-Rundles C.

J Allergy Clin Immunol Pract. 2020 Jan;8(1):283-291.e1. doi: 10.1016/j.jaip.2019.08.012. Epub 2019 Aug 17.

PMID:
31430592
6.

Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.

Lai R, O'Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, Albitar M.

Cancer. 2002 Sep 1;95(5):1071-5.

7.

Anti-BCMA antibodies in the future management of multiple myeloma.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E.

Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326. doi: 10.1080/14737140.2019.1586539. Epub 2019 Mar 18.

PMID:
30810049
8.

Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.

Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, Patil S, Udd K, Bujarski S, Cao J, Hekmati T, Ghermezi M, Zhou M, Wang EY, Tanenbaum EJ, Zahab B, Schlossberg R, Yashar MA, Wang CS, Tang GY, Spektor TM, Berenson JR.

Leuk Res. 2019 Jun;81:62-66. doi: 10.1016/j.leukres.2019.04.008. Epub 2019 Apr 18.

PMID:
31035033
9.

Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.

Li H, Yi SH, Xiong WJ, Liu HM, Lyu R, Wang TY, Liu W, Zhong SZ, Yu Z, Zou DH, Xu Y, An G, Li ZJ, Qiu LG.

Chin Med J (Engl). 2017 Jan 20;130(2):135-142. doi: 10.4103/0366-6999.197978.

10.

A proliferation-inducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia.

Tecchio C, Nichele I, Mosna F, Zampieri F, Leso A, Al-Khaffaf A, Veneri D, Andreini A, Pizzolo G, Ambrosetti A.

Eur J Haematol. 2011 Sep;87(3):228-34. doi: 10.1111/j.1600-0609.2011.01650.x. Epub 2011 Jul 26.

PMID:
21595749
11.

Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.

Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A.

Eur J Haematol. 2006 Jan;76(1):51-7.

PMID:
16343271
12.

Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.

Srivastava MD, Srivastava A, Srivastava BI.

Leuk Lymphoma. 1994 Jan;12(3-4):241-51.

PMID:
7909467
13.

[Assessment of selected markers of apoptosis and angiogenesis in chronic lymphocytic leukemia].

Motyčková M, Smolej L, Andrýs C, Rezáčová V, Reháček V, Simkovič M, Belada D, Zák P.

Vnitr Lek. 2013 Sep;59(9):782-93. Czech.

PMID:
24073950
14.

Increased serum C-reactive protein levels are associated with shorter survival and development of second cancers in chronic lymphocytic leukemia.

Herishanu Y, Polliack A, Shenhar-Tsarfaty S, Weinberger R, Gelman R, Ziv-Baran T, Zeltser D, Shapira I, Berliner S, Rogowski O.

Ann Med. 2017 Feb;49(1):75-82. doi: 10.1080/07853890.2016.1232860. Epub 2016 Nov 3.

PMID:
27595291
15.

Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.

Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK, Armitage RJ, Andreeff M.

Br J Haematol. 1998 Jan;100(1):135-41.

PMID:
9450802
16.

Serum levels of tetranectin, intercellular adhesion molecule-1 and interleukin-10 in B-chronic lymphocytic leukemia.

Kamper EF, Papaphilis AD, Angelopoulou MK, Kopeikina LT, Siakantaris MP, Pangalis GA, Stavridis JC.

Clin Biochem. 1999 Nov;32(8):639-45.

PMID:
10638947
17.

Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.

Robak T, Wierzbowska A, Błasińska-Morawiec M, Korycka A, Błoński JZ.

Mediators Inflamm. 1999;8(6):277-86.

18.

Decreased dickkopf-1 levels in chronic lymphocytic leukemia and increased osteopontin levels in non-Hodgkin's lymphoma at initial diagnosis: Could they be playing roles in pathogenesis?

Pamuk GE, Uyanik MS, Pamuk ON, Maden M, Tapan U.

Hematology. 2015 Jun;20(5):267-71. doi: 10.1179/1607845414Y.0000000205. Epub 2014 Oct 1.

PMID:
25271869
19.

Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations.

Sharma M, Tyagi S, Tripathi P, Seth T.

Blood Res. 2018 Sep;53(3):205-209. doi: 10.5045/br.2018.53.3.205. Epub 2018 Sep 28.

20.

Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance.

Van Damme M, Crompot E, Meuleman N, Maerevoet M, Mineur P, Bron D, Lagneaux L, Stamatopoulos B.

Clin Epigenetics. 2016 Dec 7;8:132. eCollection 2016.

Supplemental Content

Support Center